Product Program year 2025 Source: CMS Open Payments

Yorvipath

Drug Endocrinology

NDC 73362-100-01

Open in the dashboard

General payments

$1,943,341

10,864 payments

Research payments

$1,458,391

1,130 payments

Through program year 2025, $1,943,341 in general payments and $1,458,391 in research payments were reported against Yorvipath (Endocrinology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2025 General $1,925,802 10,810
2025 Research $1,458,391 1,130
2024 General $17,539 54

Breakdown

Who paid General payments · program years 2024–2025
  1. Ascendis Pharma, Inc. $1,943,341 10,864 payments
Top recipients General payments · program year 2025
  1. Lynn Kohlmeier Endocrinology, Diabetes & Metabolism · Spokane, WA $95,745 5% · 89 payments
  2. Mark Warren Endocrinology, Diabetes & Metabolism · Greenville, NC $87,206 5% · 93 payments
  3. Tamara Vokes Endocrinology, Diabetes & Metabolism · Chicago, IL $85,609 4% · 61 payments
  4. Rodney Snow Endocrinology, Diabetes & Metabolism · Nashville, TN $84,304 4% · 67 payments
  5. Elena Christofides Endocrinology, Diabetes & Metabolism · Columbus, OH $80,254 4% · 117 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Endocrinology, Diabetes & Metabolism Internal Medicine $1,606,695 84% · 1,992 practitioners
  2. Internal Medicine $121,388 6% · 278 practitioners
  3. Surgery $79,459 4% · 33 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $28,115 1% · 470 practitioners
  5. Nephrology Internal Medicine $26,428 1% · 187 practitioners

The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $234,171 12% · 342 recipients
  2. California $174,704 9% · 353 recipients
  3. North Carolina $152,588 8% · 108 recipients
  4. Ohio $150,412 8% · 183 recipients
  5. Michigan $135,094 7% · 143 recipients

The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

10,864 general · 1,130 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record